| 引用本文: |
周梦红, 曾勇, 王月爱, 陈露阳, 雍苏南.天苓止眩片调控SIRT3改善高血压大鼠心脏微血管内皮细胞损伤的机制研究[J].湖南中医药大学学报,2026,46(10):1963-1972[点击复制] |
|
| |
|
|
| 本文已被:浏览 354次 下载 353次 |
| 天苓止眩片调控SIRT3改善高血压大鼠心脏微血管内皮细胞损伤的机制研究 |
| 周梦红,曾勇,王月爱,陈露阳,雍苏南 |
| (湖南中医药大学第一附属医院, 湖南 长沙 410007) |
| 摘要: |
| 目的 探讨天苓止眩片调控沉默信息调节因子3(SIRT3)改善高血压环境下的大鼠心脏微血管内皮细胞(RCMECs)损伤的分子机制。方法 采用1 μg·mL-1脂多糖(LPS)联合0.2 μmol·L-1血管紧张素Ⅱ(AngⅡ)干预24 h,模拟高血压环境下RCMECs损伤模型,设置正常组、模型组、SIRT3阻断剂组、天苓止眩片含药血清组和SIRT3阻断剂+天苓止眩片含药血清组。采用CCK-8法筛选天苓止眩片含药血清给药浓度。采用细胞成像分析系统观察各组RCMECs形态结构变化;采用CCK-8法检测RCMECs存活率。采用荧光探针法检测RCMECs线粒体活性氧(mtROS)水平;采用ELISA检测细胞上清液中肿瘤坏死因子-α(TNF-α)和白细胞介素-1β(IL-1β)含量;采用免疫荧光和Western blot分别检测RCMECs中SIRT3、缺氧诱导因子1α(HIF-1α)、核因子κB亚基p65(p65)、NOD样受体热蛋白结构域相关蛋白3(NLRP3)和胱天蛋白酶-1(Caspase-1)蛋白表达水平。结果 天苓止眩片含药血清以10%浓度进行给药。与正常组比较,模型组形态明显受损,RCMECs存活率降低(P<0.01),mtROS水平、TNF-α、IL-1β含量均升高(P<0.01),SIRT3蛋白表达水平降低(P<0.01),HIF-1α、p65、NLRP3、Caspase-1蛋白表达水平均升高(P<0.01)。与模型组比较,SIRT3阻断剂组、SIRT3阻断剂+天苓止眩片含药血清组RCMECs形态结构损伤未明显改善,而天苓止眩片含药血清组RCMECs形态结构损伤明显改善;SIRT3阻断剂组RCMECs存活率、SIRT3蛋白表达水平均降低(P<0.05,P<0.01),mtROS水平、TNF-α、IL-1β含量、HIF-1α、p65、NLRP3、Caspase-1蛋白表达水平均升高(P<0.01);SIRT3阻断剂+天苓止眩片含药血清组、天苓止眩片含药血清组RCMECs存活率、SIRT3蛋白表达水平均升高(P<0.01),mtROS水平、TNF-α、IL-1β含量、HIF-1α、p65、NLRP3、Caspase-1蛋白表达水平均降低(P<0.05,P<0.01)。与SIRT3阻断剂组比较,SIRT3阻断剂+天苓止眩片含药血清组、天苓止眩片含药血清组RCMECs存活率、SIRT3蛋白表达水平均升高(P<0.01),mtROS水平、TNF-α、IL-1β含量、HIF-1α、p65、NLRP3、Caspase-1蛋白表达水平均降低(P<0.05,P<0.01)。与天苓止眩片含药血清组比较,SIRT3阻断剂+天苓止眩片含药血清组RCMECs存活率、SIRT3蛋白表达水平降低(P<0.05),mtROS水平、TNF-α和IL-1β含量、HIF-1α、p65、NLRP3、Caspase-1蛋白表达水平均升高(P<0.05)。结论 天苓止眩片含药血清可能通过上调SIRT3,进而抑制HIF-1α/p65与NLRP3/Caspase-1两条通路蛋白表达异常升高,减少mtROS、TNF-α、IL-1β释放,最终改善高血压环境下的RCMECs损伤。 |
| 关键词: 高血压|天苓止眩片|心脏微血管内皮细胞|沉默信息调节因子3|氧化应激|炎症小体 |
| DOI:10.3969/j.issn.1674-070X.2026.10.001 |
| 投稿时间:2026-07-06 |
| 基金项目:湖南省自然科学基金医卫联合项目(2024JJ9418,2026JJ82085);湖南省教育厅科学研究项目(25A0303);长沙市2025年度指导性科技计划项目(kzd2501108);湖南中医药大学院校联合基金项目(2024XYLH012)。 |
|
| Mechanism of Tianling Zhixuan Tablets in ameliorating cardiac microvascular endothelial cell injury by regulating SIRT3 in hypertensive rats |
| ZHOU Menghong, ZENG Yong, WANG Yueai, CHEN Luyang, YONG Sunan |
| (The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China) |
| Abstract: |
| Objective To investigate the molecular mechanism by which Tianling Zhixuan Tablets (TLZXT) regulate sirtuin 3 (SIRT3) to ameliorate injury of rat cardiac microvascular endothelial cells (RCMECs) under hypertensive conditions. Methods An RCMEC injury model under simulated hypertensive conditions was established by intervention with 1 μg·mL-1 lipopolysaccharide (LPS) combined with 0.2 μmol·L-1 angiotensin Ⅱ (AngⅡ) for 24 h. The cells were randomized into normal group, model group, SIRT3 inhibitor group, TLZXT medicated serum group, and SIRT3 inhibitor+TLZXT medicated serum group. The CCK-8 assay was used to screen the administration concentration of TLZXT medicated serum. A cell imaging analysis system was used to observe morphological and structural changes of RCMECs in each group; the CCK-8 assay was used to determine RCMEC viability; a fluorescent probe method was used to examine mitochondrial reactive oxygen species (mtROS) levels in RCMECs; ELISA was used to determine the content of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) in the cell supernatant; immunofluorescence and Western blot were used to determine the protein expression levels of SIRT3, hypoxia inducible factor-1α (HIF-1α), nuclear factor κB p65 (p65), NOD-like receptor family pyrin domain containing protein 3 (NLRP3), and Caspase-1 in RCMECs. Results A 10% TLZXT medicated serum was used in subsequent experiments. Compared with the normal group, the model group showed obvious morphological damage, decreased RCMEC viability (P<0.01), increased mtROS levels as well as TNF-α and IL-1β content (P<0.01), decreased SIRT3 protein expression (P<0.01), and increased protein expression levels of HIF-1α, p65, NLRP3, and Caspase-1 (P<0.01). Compared with the model group, the SIRT3 inhibitor group and the SIRT3 inhibitor+TLZXT medicated serum group showed no obvious amelioration in morphological and structural damage of RCMECs, whereas the TLZXT medicated serum group showed obvious amelioration in morphological and structural damage of RCMECs; in the SIRT3 inhibitor group, RCMEC viability and SIRT3 protein expression were decreased (P<0.05, P<0.01), while mtROS levels, TNF-α and IL-1β content, and protein expression levels of HIF-1α, p65, NLRP3, and Caspase-1 were increased (P<0.01); in the SIRT3 inhibitor+TLZXT medicated serum group and the TLZXT medicated serum group, RCMEC viability and SIRT3 protein expression were increased (P<0.01), while mtROS levels, TNF-α and IL-1β content, and protein expression levels of HIF-1α, p65, NLRP3, and Caspase-1 were decreased (P<0.05, P<0.01). Compared with the SIRT3 inhibitor group, the SIRT3 inhibitor+TLZXT medicated serum group and the TLZXT medicated serum group showed increased RCMEC viability and SIRT3 protein expression (P<0.01), and decreased mtROS levels, TNF-α and IL-1β content, and protein expression levels of HIF-1α, p65, NLRP3, and Caspase-1 (P<0.05, P<0.01). Compared with the TLZXT medicated serum group, the SIRT3 inhibitor+TLZXT medicated serum group showed decreased RCMEC viability and SIRT3 protein expression (P<0.05), and increased mtROS levels, TNF-α and IL-1β content, and protein expression levels of HIF-1α, p65, NLRP3, and Caspase-1 (P<0.05). Conclusion TLZXT medicated serum may up-regulate SIRT3, thereby inhibiting the abnormally elevated protein expression of the HIF-1α/p65 and NLRP3/Caspase-1 pathways, reducing the release of mtROS, TNF-α and IL-1β, and ultimately ameliorating RCMECs injury under hypertensive conditions. |
| Key words: hypertension|Tianling Zhixuan Tablets|cardiac microvascular endothelial cells|sirtuin 3|oxidative stress|inflammasome |
|
 二维码(扫一下试试看!) |
|
|
|
|